Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BYFrontiers in immunology

Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures

  • Xue Peng Rao1
  • Xin Chang Zou1
  • Xiang Liu1
  • Lie Yu Xu2
  • Jian Biao Huang3
  • Yu Yang Yuan4
  • Tao Chen1
  • Tao Zeng1
4 affiliations
  1. 1Department of Urology, Second Affiliated Hospital of Nanchang University, Jiangxi Medical College , ,
  2. 2Department of Urology, Jiangxi Provincial People’s Hospital , ,
  3. 3Jiangxi Cancer Hospital & Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College , ,
  4. 4Department of Urology, First Affiliated Hospital of Nanchang University , ,
Read full textPDFCite

Related

  1. Not all major pathological responses are equal: prognostic heterogeneity and risk stratification after neoadjuvant chemoimmunotherapy in resectable NSCLC.
    Jiong Lin, Haijie Xu, Jiming Tang +8
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  2. A pretreatment hormonal-nutritional-immune score for locally advanced gastric cancer receiving neoadjuvant immunochemotherapy: a multicenter retrospective cohort study
    Zhiqiang Wang, Jie Zheng, Le Wang +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  3. The Ecological Price of Segregation: Socioeconomic Stratification Structures Urban Bird and Vegetation Distribution
    Rodrigo Mutis, Sara Gabriela Acosta-Morales
    EcoEvoRxivPreprintCC BY 4.0Full textEcologyEcoEvoRxiv
  4. Expression of TRPMPZQ in excitable cells and sensory structures throughout the Schistosoma mansoni lifecycle
    C. M. Rohr, F. Blow, S.-K. Park +2
    bioRxivPreprintCC BY-NC-NDFull textMicrobiologybioRxiv
  5. FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
    Penghui Liu, Na Li, Jiwu Guo +3
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{rao2026neoadjuvant,
  title = {{Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures}},
  author = {Xue Peng Rao and Xin Chang Zou and Xiang Liu and Lie Yu Xu and Jian Biao Huang and Yu Yang Yuan and Tao Chen and Tao Zeng},
  journal = {Frontiers in immunology},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13655032},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures
AU  - Xue Peng Rao
AU  - Xin Chang Zou
AU  - Xiang Liu
AU  - Lie Yu Xu
AU  - Jian Biao Huang
AU  - Yu Yang Yuan
AU  - Tao Chen
AU  - Tao Zeng
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in immunology
UR  - https://europepmc.org/article/PMC/PMC13655032
SN  - 1664-3224
ER  -